Severe 6-thioguanine-induced marrow aplasia in a child with acute lymphoblastic leukemia and inherited thiopurine methyltransferase deficiency

American Journal of Pediatric Hematology/Oncology

Volumn 22, Issue 5, 2000, Pages 441-445

  McBride, Kim L ^a,c   Gilchrist, Gerald S ^b,c,d   Smithson, W Anthony ^b,c,d   Weinshilboum, Richard M ^c,d   Szumlanski, Carol L ^c  

^a Division of Pediatric Cardiology Pediatrics and Adolescent Medicine   (United States)

^b Departments of Pediatric Hematology and Oncology   (United States)

^c MAYO CLINIC   (United States)

^d MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

Complications; Drug eruption; Pharmacogenetics; Therapy

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; METHYLTRANSFERASE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; BONE MARROW; CASE REPORT; CHILD; DRUG EFFECT; HUMAN; MALE; PATHOLOGY;

ANTIMETABOLITES, ANTINEOPLASTIC; BONE MARROW; CHILD; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; METHYLTRANSFERASES; THIOGUANINE;

EID: 0034263837     PISSN: 01928562     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200009000-00011     Document Type: Article

References (30)

1. Snow JL, Gibson LE. A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients. J Am Acad Dermatol 1995; 32: 114-6.
2. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32: 651-62.
3. Weinshilboum RM, Otterness DM, Szumlanski CL. Methylation pharmacogenetics: Catechol-O methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Ann Rev Pharmacol Toxicol 1999; 39: 19-52.
4. Otterness D, Szumlanski C, Lennard L, et al. Human thiopurine methyltransferase pharmacgenetics: Gene sequence polymorphisms. Clin Pharmacol Ther 1997; 62: 60-73.
5. Otterness DM, Szmulanski CL, Wood TC, Weinshilboum RM. Human thiopurine methyltransferase pharmacogenetics-kindred with a terminal exon splice junction mutation that results in loss of activity. J Clin Invest 1998; 101: 1036-44.
6. Szmulanski C, Otterness D, Her C, et al. Thiopurine metyltransferase pharmacogenetics: Human gene cloning and characterization of a common polymorphism. DNA Cell Biol 1996; 15: 17-30.
7. Harms D, Janka-Schaub GE, Erb N, et al. Randomized comparison of 6-mercaptopurine vs 6-thioguanine in maintenance treatment of childhood acute lymphoblastic leukemia: Preliminary results [abstract]. Br J Haematol 1996; 93(Suppl 2): 58.
8. Lancaster DL, Lennard L, Rowland K, et al. Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: A comparison of haematological toxicity and drug metabolite concentrations. Br J Haematol 1998; 102: 439-43.
9. Lilleyman JS, Lennard L. Mercaptopurine metabolism and the risk of relapse in childhood lymphoblastic leukemia. Lancet 1994; 343: 1188-90.
10. Deininger M, Szumlanski CL, Otterness DM, et al. Purine substrates fro human thiopurine methyltransferase. Biochem Pharmacol 1994; 11: 2135-38.
11. Weinshilboum RM. Methylation pharmacogenetics: Thiopurine methyltransferase as a model system. Xenobiotica 1992; 22: 1055-71.
12. Schmeiglow K, Bruunshuus I. 6-thioguanine nucleotide accumulation in red cells during maintenance chemotherapy for childhood acute lymphoblastic leukemia, and its relation to leucopenia. Cancer Chemother Pharmacol 1990; 26: 288-92.
13. Adamson PC, Poplack DG, Ballis FM. The cytotoxicity of thioguanine vs. mercaptopurine in acute lymphoblastic leukemia. Leuk Res 1994; 18: 805-10.
14. Lennard L, Davies HA, Lilleyman JS. Is 6-thioguanine more appropriate than 6-mercaptopurine for children with ALL? Br J Cancer 1993; 68: 186-90.
15. Leipold G, Schutz E, Haas JP, Oellerich M. Azathioprine-induced severe pancytopenia due to a homozygous two-point mutation of the thiopurine methyltransferase gene in a patient with juvenile HLA-B27-associated spondylarthritis. Arthritis Rheum 1997; 40: 1896-8.
16. Anstey A, Lennard L, Mayou SC, Kirby JD. Pancytopenia related to azathioprine-an enzyme deficiency caused by a common genetic polymorphism: A review. J Royal Soc Med 1992; 85: 752-6.
17. McLeod HL, Miller DR, Evans WE. Azathioprine induced myelosuppression in thiopurine methyltransferase deficient heart transplant patient. Lancet 1993; 341: 1151.
18. Schutz E, Gummert J, Mohr FW, et al. Azathioprine myelotoxicity related to elevated 6-thioguanine nucleotides in heart transplantation. Transplant Proc 1995; 27: 1298-300.
19. Ben Ari Z, Mehta A, Lennard L, Burroughs AK. Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis. J Hepatol 1995; 23: 351-4.
20. Escousse A, Mousson C, Santona L, et al. Azathioprine-induced pancytopenia in homozygous thiopurine methyltransferase-deficient renal transplant recipients: A family study. Transplant Proc 1995; 27: 1739-42.
21. Andersen JB, Szumlanski C, Weinshilboum RM, Schmiegelow K. Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency. Acta Paediatr 1998; 87: 108-11.
22. Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr 1991; 119: 985-9.
23. Lennard L, Gibson BE, Nicole T, Lilleyman JS. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child 1993; 69: 577-9.
24. Lennard L, Lewis IJ, Michelagnoli M, Lilleyman JS. Thiopurine methyltransferase deficiency in childhood lymphoblastic leukaemia: 6-mercaptopurine dosage strategies. Med Pediatr Oncol 1997; 29: 252-5.
25. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukemia. Lancet 1990; 336: 225-9.
26. Lennard L, Welch JC, Lilleyman JS. Thiopurine drugs in the treatment of childhood leukaemia: The influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity. Br J Clin Pharmacol 1997; 44: 455-61.
27. Lennard L, van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989; 46: 149-54.
28. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-mehtyltransferase deficiency: Genetic basis for azathiprine and mercaptopurine intolerance. Ann Intern Med 1997; 126: 608-14.
29. Krynetski EY, Evans WE. Pharmacogenetics of cancer therapy: Getting personal. Am J Hum Genet 1998; 63: 11-6.
30. Lennard L, Lilleyman JS. Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase genetic polymorphism. Ther Drug Monit 1996; 18: 328-34.